Jul 10, 2026TrialAn Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover Oral Bioequivalence Study to Compare Empagliflozin / Metformin 25 mg/ 1000 mg Extended-Release Tablet Versus Synjardy XR Tablets 25mg/1000mg in Fasting Condition.
Jul 10, 2026TrialAn Open Label, Balanced, Randomized, Single Dose, Three Treatment, Three Sequence, Three Period, Three Way Crossover Oral Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets in Fed Condition.
Jul 9, 2026TrialAn Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets and Twymeeg Tablets 500 mg in Healthy, Adult, Human Participants Under Fasting Condition.
Jul 9, 2026TrialAn Open Label, Randomized, Two-period, Two Treatment, Two-sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study to Compare Empagliflozin/ Linagliptin/ Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR (Empagliflozin, Linagliptin, and Metformin Hydrochloride Extended-release Tablets) 25 mg/5 mg/1000 mg in Fed Condition.